New Functional Data on Our Spike Monoclonal Antibodies
Data on our anti-SARS-CoV-2 Spike S1 monoclonal antibodies shows that they are suitable for the investigation of antibody, antigen and receptor binding interactions between different Spike variants including the E484K receptor-binding domain mutation. The data shown here includes:
• Differential binding of our anti-Spike S1 antibodies against our E484K Spike S1 protein
• Differential inhibition of binding between our Wuhan-Hu-1 Spike RBD and ACE2 by our anti-Spike S1 antibodies
• Neutralisation of Wuhan-Hu-1 Spike-pseudotyped lentivirus by our anti-Spike S1 antibodies
Reagents
For product-specific information on our antibodies, E484K Spike S1 and ACE2 receptor proteins, please click on the buttons below:
Antibodies
Proteins
Functional Binding Data
The following ELISA and pseudotype neutralisation data are shown for these products below:
ELISA: Anti-RBD Monoclonal Antibodies vs. Spike S1 (E484K Mutant)
Competitive ELISA: ACE2 vs. Anti-RBD Monoclonal Antibodies Against RBD-Coated Plates
Competitive ELISA: ACE2 vs. Anti-RBD Monoclonal Antibodies Against RBD-Coated Plates
Pseudotype micro-neutralisation assays were carried out by Dr Diego Cantoni, Dr Martin Mayora-Neto and Dr Nigel Temperton at the Viral Pseudotype Unit, Medway School of Pharmacy, University of Kent.